DexCom, Inc. $DXCM Stock Position Increased by Peregrine Capital Management LLC

Peregrine Capital Management LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.9% during the 4th quarter, HoldingsChannel reports. The fund owned 657,819 shares of the medical device company’s stock after purchasing an additional 126,891 shares during the period. DexCom accounts for approximately 1.3% of Peregrine Capital Management LLC’s portfolio, making the stock its 17th biggest holding. Peregrine Capital Management LLC’s holdings in DexCom were worth $43,659,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. SJS Investment Consulting Inc. increased its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the period. Financial Consulate Inc. acquired a new position in shares of DexCom in the third quarter worth $29,000. CVA Family Office LLC raised its holdings in shares of DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. ORG Partners LLC boosted its position in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 281 shares during the last quarter. Finally, Spire Wealth Management grew its stake in DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 305 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.32% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on DXCM. Sanford C. Bernstein restated an “outperform” rating and set a $86.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, February 13th. Wells Fargo & Company cut their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Barclays reissued an “underweight” rating and set a $72.00 price objective (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Finally, Piper Sandler restated an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.50.

DexCom Price Performance

DXCM stock traded down $0.10 during trading on Thursday, hitting $63.31. The company had a trading volume of 118,793 shares, compared to its average volume of 4,829,706. The company has a fifty day moving average price of $67.04 and a two-hundred day moving average price of $66.67. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a market cap of $24.43 billion, a P/E ratio of 30.26, a P/E/G ratio of 1.22 and a beta of 1.55. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.45 earnings per share. Equities research analysts expect that DexCom, Inc. will post 2.49 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.